Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction

Experimental Physiology

Volumn 93, Issue 8, 2008, Pages 982-993

  Zhan, Enbo ^a   Keimig, Thomas ^a   Xu, Jiang ^a   Peterson, Edward ^a   Ding, Jennifer ^a   Wang, Fangfei ^a   Yang, Xiao Ping ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESTROGEN THERAPY; FEMALE; HEART DILATATION; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; MORTALITY; MOUSE; NONHUMAN;

EID: 47349117387     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2008.042788     Document Type: Article

References (47)

1. Adams KF Jr., Sueta CA, Gheorghiade M, O'Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J & Califf RM, for the FIRST Investigators (1999). Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 99, 1816 1821.
2. Alexandersen P, Tankó LB, Bagger YZ, Qin G & Christiansen C (2006). The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 9, 108 118.
3. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohé C & Doevendans PA (2006). Estrogen receptor β protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26, 1524 1530.
4. Barrett-Connor E (1997). Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95, 252 264.
5. Beer S, Reincke M, Kral M, Callies F, Strömer H, Dienesch C, Steinhauer S, Ertl G, Allolio B & Neubauer S (2007). High-dose 17β-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat. Basic Res Cardiol 102, 9 18.
6. Bittner V (2006). Menopause and cardiovascular risk. Cause or consequence? J Am Coll Cardiol 47, 1984 1986.
7. Brett KM & Madans JH (1995). Long-term survival after coronary heart disease. Comparisons between men and women in a national sample. Ann Epidemiol 5, 25 32.
8. Cavasin MA, Sankey SS, Yu AL, Menon S & Yang XP (2003). Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 284, H1560 H1569.
9. Cavasin MA, Tao Z, Menon S & Yang XP (2004). Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci 75, 2181 2192.
10. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP & Winston M (1993). Cardiovascular disease in women. Circulation 88, 1999 2009.
11. Ertl G & Frantz S (2005). Healing after myocardial infarction. Cardiovasc Res 66, 22 32.
12. Gambrell RD Jr. & Natrajan PK (2006). Moderate dosage estrogen-androgen therapy improves continuation rates in postmenopausal women: impact of the WHI reports. Climacteric 9, 224 233.
13. Gao X-M, Xu Q, Kiriazis H, Dart AM & Du XJ (2005). Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc Res 65, 469 477.
14. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, Mortola J, Watts N, Yang HM, Banav N, Brennan JJ & Nolan JC (1997). Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 157, 2609 2615.
15. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE & Stampfer MJ (2000). A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133, 933 941.
16. Grodstein F, Manson JE & Stampfer MJ (2006). Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15, 35 44.
17. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH & Speizer FE (1997). Postmenopausal hormone therapy and mortality. N Engl J Med 336, 1769 1775.
18. Hamada H, Kim MK, Iwakura A, Ii M, Thorne T, Qin G, Asai J, Tsutsumi Y, Sekiguchi H, Silver M, Wecker A, Bord E, Zhu Y, Kishore R & Losordo DW (2006). Estrogen receptors α and β mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 114, 2261 2270.
19. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BC, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR & Torner J, for the WHI Investigators (2006). Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113, 2425 2434.
20. Hügel S, Reincke M, Strömer H, Winning J, Horn M, Dienesch C, Mora P, Schmidt HH, Allolio B & Neubauer S (1999). Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. J Am Coll Cardiol 34, 1427 1434.
21. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E & Hunninghake D, for the HERS Research Group (2002). Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288, 58 66.
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B & Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280, 605 613.
23. Hunter JC, Kostyak JC, Novotny JL, Simpson AM & Korzick DH (2007). Estrogen deficiency decreases ischemic tolerance in the aged rat heart: roles of PKCδ, PKCε, Akt, and GSK3β. Am J Physiol Regul Integr Comp Physiol 292, R800 R809.
24. Isles CG, Hole DJ, Hawthorne VM & Lever AF (1992). Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet 339, 702 706.
25. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, Kishore R, Zhu Y, Qin G, Silver M, Thorne T, Eaton L, Masuda H, Asahara T & Losordo DW (2006). Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113, 1605 1614.
26. Koide Y, Tamura K, Suzuki A, Kitamura K, Yokoyama K, Hashimoto T, Hirawa N, Kihara M, Ohno S & Umemura S (2003). Differential induction of protein kinase C isoforms at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats. Hypertens Res 26, 421 426.
27. Lerner DJ & Kannel WB (1986). Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111, 383 390.
28. Liu Y-H, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E & Carretero OA (1997). Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99, 1926 1935.
29. Nishida M, Okumura Y, Fujimoto S, Shiraishi I, Itoi T & Hamaoka K (2005). Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun 332, 11 16.
30. Pedram A, Razandi M, Aitkenhead M & Levin ER (2005). Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 280, 26339 26348.
31. Pelzer T, Loza PA, Hu K, Bayer B, Dienesch C, Calvillo L, Couse JF, Korach KS, Neyses L & Ertl G (2005). Increased mortality and aggravation of heart failure in estrogen receptor-β knockout mice after myocardial infarction. Circulation 111, 1492 1498.
32. Pines A, Sturdee DW & Birkhäuser M, on behalf of the International Menopause Society (2006). More data on hormone therapy and coronary heart disease: comments on recent publications from the WHI and Nurses' Health Study. Climacteric 9, 75 76.
33. Reis SE, Holubkov R, Young JB, White BG, Cohn JN & Feldman AM (2000). Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J Am Coll Cardiol 36, 529 533.
34. Rossouw JE, Andersen GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford FA, Howard BV, Johnson KC, Kotchen JM & Ockene J, Writing Group for the Women's Health Initiative investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321 333.
35. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG & Grady D, for the National Registry of Myocardial Infarction-3 investigators (2001). Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 104, 2300 2304.
36. Simonis G, Briem SK, Schoen SP, Bock M, Marquetant R & Strasser RH (2007). Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem 305, 103 111.
37. Simpson ER, Clyne C, Speed C, Rubin G & Bulun S (2001). Tissue-specific estrogen biosynthesis and metabolism. Ann N Y Acad Sci 949, 58 67.
38. Simpson ER & Davis SR (2001). Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142, 4589 4594.
39. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE & Hennekens CH (1991). Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses health study. N Engl J Med 325, 756 762.
40. Tamura T, Said S & Gerdes AM (1999). Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 33, 676 680.
41. Tang AC, Nakazawa M, Romeo RD, Reeb BC, Sisti H & McEwen BS (2005). Effects of long-term estrogen replacement on social investigation and social memory in ovariectomized C57BL/6 mice. Horm Behav 47, 350 357.
42. van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ & Doevendans PA (2001). 17β-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104, 1419 1423.
43. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, Celestin F, Grohe C, Mendelsohn ME & Karas RH (2003). 17-β-Estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol 41, 2084 2092.
44. Wang M, Crisostomo P, Wairiuko GM & Meldrum DR (2006). Estrogen receptor-α mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290, H2204 H2209.
45. Wenger NK, Speroff L & Packard B (1993). Cardiovascular health and disease in women. N Engl J Med 329, 247 256.
46. Willett WC, Manson JE, Grodstein F, Stampfer MJ & Colditz GA (2006). Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial". Am J Epidemiol 163, 1067 1068.
47. Yang X-P, Liu YH, Rhaleb NE, Kurihara N, Kim HE & Carretero OA (1999). Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol Heart Circ Physiol 277, H1967 H1974.